Adrenal hyperplasia due to abiraterone: One case report and literature review
10.3760/cma.j.cn311282-20240412-00147
- VernacularTitle:阿比特龙致肾上腺增生一例报道并文献复习
- Author:
Haibo HUANG
1
;
Jiping ZHANG
;
Peng WANG
Author Information
1. 连云港市第一人民医院内分泌科，徐州医科大学附属连云港医院，连云港 222000
- Publication Type:Journal Article
- Keywords:
Abiraterone;
Hypokalemia;
Mineralocorticoid excess;
Adrenal hyperplasia
- From:
Chinese Journal of Endocrinology and Metabolism
2024;40(12):1065-1067
- CountryChina
- Language:Chinese
-
Abstract:
Abiraterone reduces androgen synthesis through inhibition of CYP17A1 activity and is therefore used in the treatment of metastatic prostate cancer. However, it can cause accumulation of mineralocorticoid intermediates and impaired production of cortisol, leading to hypertension, hypokalemia, and adrenocortical insufficiency. This case report presents a prostate cancer patient who developed hypokalemia following treatment with abiraterone. Endocrine testing revealed that abiraterone induced hormonal alterations and contributed to adrenal hyperplasia, which was implicated in the onset of hypokalemia.
